Targeting JAK2 in the therapy of myeloproliferative neoplasms.

  title={Targeting JAK2 in the therapy of myeloproliferative neoplasms.},
  author={Mamatha M. Reddy and Anagha Deshpande and Martin Sattler},
  journal={Expert opinion on therapeutic targets},
  volume={16 3},
INTRODUCTION Myeloproliferative neoplasms (MPNs) are a group of stem cell diseases, including polycythemia vera, essential thrombocythemia and primary myelofibrosis. Currently, there is no curative therapy for these diseases other than bone marrow transplant; therefore there is an apparent need for palliative treatment. MPNs are frequently associated with activating mutations in JAK2; small-molecule drugs targeting this molecule have entered clinical trials. AREAS COVERED In this review novel… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS